News Ipsen doubles up in TCEs for cancer, adding Biomunex drug Ipsen has expanded its oncology pipeline by licensing a T cell engager (TCE) therapy from Paris-based startup Biomunex for up to $610m.
News Immunocore's rare eye cancer drug backed by NICE Patients in England with a rare form of eye cancer will be able to access Kimmtrak, a TCR therapy from Immunocore, after NICE changes its position.
News Alligator slashes workforce and pares down its pipeline Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce.
News Kisqali gets early breast cancer approval in Europe Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours
News Medigene axes staff and refocuses its TCR pipeline Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline
News Roche buys off-the-shelf CAR-T player Poseida for $1bn Roche has upgraded its partnership with off-the-shelf CAR-T therapy specialist Poseida to a $1 billion-plus takeover bid
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.